Over-nutrition, obesity and insulin resistance in the development of β-cell dysfunction

Current Diabetes Reviews

Volumn 8, Issue 2, 2012, Pages 76-83

  Gupta, Deepashree ^a   Krueger, Charles B ^a   Lastra, Guido ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Cell; Cell dysfunction; Insulin resistance; Obesity; Type 2 diabetes mellitus

Indexed keywords

FAS LIGAND; FLICE INHIBITORY PROTEIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TRANSPORTER 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCRETIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; REACTIVE OXYGEN METABOLITE; RHEB PROTEIN; TUBERIN; TUMOR NECROSIS FACTOR ALPHA;

CELL FUNCTION; CELL SURVIVAL; CELL VIABILITY; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; EXOCYTOSIS; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVERNUTRITION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENERGY INTAKE; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; NUTRITIONAL STATUS; OBESITY; UNITED STATES;

EID: 84857730813     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339912799424564     Document Type: Review

References (94)

1. Venkat Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290: 1884-90.
2. Lastra G, Manrique CM, Govindarajan G, Whaley-Connell A, Sowers JR. Insights into the emerging Cradiometabolic Prevention and Management of Diabetes Mellitus. Expert Opin Pharmacother 2005; 6: 2209-21.
3. Arner P, Pollare T, Lithell H. Different etiologies of type 2 (noninsulin-dependent) diabetes mellitus in obese and nonobese subjects. Diabetologia 1991; 34: 483-7.
4. Banerji M, Chaiken RL, Gordon D, Kral J, Lebovitz H. Does intrabdominal adipose tissue in black men determine whether NIDM is insulin-resistant or insulin-sensitive?. Diabetes 1995; 44: 141-6.
5. Taniguchi A, Nakai Y, Doi K, et al. Insulin sensitivity, insulin secretion, and glucose effectiveness in obese subjects: a minimal model analysis. Metabolism 1995; 44: 1397-400.
6. Lastra G, Manrique C. The Expanding Role of Oxidative Stress, Renin Angiotensin System, and β-Cell Dysfunction in the Cardiometabolic Syndrome and Type 2 Diabetes Mellitus. Antioxidants & Redox Signaling 2007; 9(7): 943-54.
7. Gerich JE. The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity. Endocrine Rev 1998; 19: 491-503.
8. Ahren B, Pacini G. Islet adaptation to insulin resistance: mechanism and implications for intervention. Diabetes Obes Metab 2005; 7: 2-8.
9. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52(1): 102-10.
10. David G. Gardner, Dolores Shoback. Greenspan's Basic & Clinical Endocrinology, 9e 2011.
11. Caumo A, Luzi L. First-phase insulin secretion: does it exist in real life? Am J Physiol Endocrinol Metab 2004: E371-E85.
12. Brunzell JD, Robertson RP, Porte D Jr, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42: 222-9.
13. Vague P, Moulin JP. The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycemia. Metabolism 1982; 31: 139-42.
14. O'Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulindependent diabetes. N Engl J Med 1988; 318: 1225-30.
15. Schmitz O, Porksen N, Pincus SM. Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. Am J Physiol 1997; 272: E218-26.
16. Turner RC, McCarthy ST, Holman RR, Harris E. Beta cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1976; 1: 1252-1254.
17. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88: 787-835.
18. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-62.
19. Seltzer HS, Allen EW, Herron Jr AL, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967; 46: 323-35.
20. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-57.
21. Nauck M, Stockmann F, Creutzfeldt W, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
22. Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloroduodenal motility in humans. Gut 2006; 55: 243-51.
23. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273: E981-E8.
24. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-73.
25. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-20.
26. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 2003; 285: E701-E7.
27. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 1994; 93: 2263-6.
28. Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002; 87: 3768-73.
29. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-9.
30. Shu L, Matveyenko AV, Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 2009; 18: 2388-99.
31. Chick WL, Like AA. Studies in the diabetic mutant mouse. Physiological factors associated with alterations in beta cell proliferation. Diabetologia 1970; 6: 243-51.
32. Bonner-Weir. Islet growth and development in the adult. Journal of Molecular Endocrinology 2000; 24: 297-302.
33. Maedler K, Sergeev P, Ris F, et al. Glucose induced B-cell production of Interleukin 1 contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-60.
34. Maedler K, Spinas GA, Lehmann R, et al. Glucose induces betacell apoptosis via upregulation of the Fas-receptor in human islets. Diabetes 2001; 50: 1683-90.
35. Laybutt DR, Glandt M, Xu G, et al. Critical reduction in beta-cell mass results in two distinct outcomes over time: adaptation with impaired glucose tolerance or decompensated diabetes. The Journal of biological chemistry 2003; 278: 2997-3005.
36. Maedler K, Fontana A, Ris F, et al. FLIP switches Fas-mediated glucose signaling in human pancreatic β cells from apoptosis to cell replication. Proc Natl Acad Sci U S A 2002; 99: 8236-41.
37. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes in women. Ann Intern Med 1995; 122: 481-6.
38. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-9.
39. Jacqueminet S, Briaud I, Rouault C, Reach G, Poitout V. Inhibition of insulin gene expression by long-term exposure of pancreatic beta-cells to palmitate is dependent upon the presence of a stimulatory glucose concentration. Metabolism 2000; 49: 532-6.
40. Harmon JS, Gleason CE, Tanaka Y, Poitout V, Robertson RP. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 2001; 50: 2481-6.
41. Robertson R, Zhou H, Harmon JS. Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes. Cell Biochem Biophys 2007; 48: 139-46.
42. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that β-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002; 51: 1437-42.
43. Prentki M, Corkey BE. Are the -cell signaling molecules malonyl CoA and cytosolic long-chain acyl CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 1996; 45: 273-83.
44. Janson J, Soeller WC, Butler PC, et al. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci 1996; 93: 7283-8.
45. Verchere CB, D'Alessio DA, Kahn SE. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci 1996; 93: 3492-6.
46. Janson J, Ashley RH, Butler PC. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999; 48: 491-8.
47. Gurlo T, Ryazantsev S, Butler PC. Evidence of proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. The American journal of pathology 2010; 176: 861-9.
48. Zraika S, Hull RL, Kahn SE. Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloidinduced beta cell apoptosis. Diabetologia 2009; 52: 626-35.
49. Matveyenko AV, Gurlo T, Butler PC. Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP induced endoplasmic reticulum stress. Diabetes 2009; 58: 906-16.
50. Masters SL, Dunne A, O'Neill LA. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 beta in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
51. Eizirik DL, Cardozo AK, Cnop M. The role of endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 29: 42-61), (Volchuk A, Ron D 2010. The endoplasmic reticulum stress response in the pancreatic β cell. Diabetes Obes Metab 2008; 12(Suppl 2): 48-57.
52. White MF. IRS Proteins and the Common Path to Diabetes. Am J Physiol Endocrinol Metab 2002; 283: E413-E22.
53. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-Specific Knockout of the Insulin Receptor in Pancreatic Beta Cells Creates an Insulin Secretory Defect Similar to that in Type 2 Diabetes. Cell 1999; 96: 329-39.
54. Myers MG Jr, White MF. Insulin Signal Transduction and the IRS Proteins. Annu Rev Pharmacol Toxicol 1996; 36: 615-58.
55. Bruning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR. Development of a Novel Polygenic Model of NIDDM in Mice Heterozygous for IR and IRS-1 Null Alleles. Cell 1997; 88: 561-72.
56. Rhodes CJ, White MF. Molecular Insights into Insulin Action and Secretion. Eur J Clin Invest 2002; 32(Suppl. 3): 3-13.
57. Lingohr MK, Dickson LM, Wrede CE, McCuaig JF, Myers MGJ, Rhodes CJ. IRS-3 Inhibits IRS-2-mediated Signaling in Pancreatic Beta-cells. Mol Cell Endocrinol 2003; 30: 85-99.
58. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 Causes Type 2 Diabetes in Mice. Nature 1998; 391: 900-4.
59. Laplante M, Sabatini DM. mTOR Signaling at a Glance. J Cell Sci 2009; 122: 3589-94.
60. Cefalu WT. Insulin Resistance: Cellular and Clinical Concepts. Exp Biol Med 2001; 226: 13-26.
61. Wang X, Proud CG. The mTOR Pathway in the Control of Protein Synthesis. Physiology 2006; 21: 362-9.
62. Tremblay F, Brûlé S, Sung Um H, et al. Identification of IRS-1 Ser-1101 as a Target of S6K1 in Nutrient and Obesity-induced Insulin Resistance. PNAS 2007; 104: 14056-61.
63. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased Activation of the Mammalian Target of Rapamycin Pathway in Liver and Skeletal Muscle of Obese Rats: Possible Involvement in Obesity-Linked Insulin Resistance. Endocrinology 2005; 146: 1473-8.
64. Zhang J, Gao Z, Yin J, Quon MJ, Ye J. S6K Directly Phosphorylates IRS-1 on Ser-270 to Promote Insulin Resistance in Response to TNF- Signaling through IKK2. The Journal of biological chemistry 2008; 283: 35375-82.
65. Herschkovitz A, Liu Y, Ilan E, Ronen D, Boura-Halfon S, Zick Y. Common Inhibitory Serine Sites Phosphorylated by IRS-1 Kinases, Triggered by Insulin and Inducers of Insulin Resistance. J Biol Chem 2007; 282: 18018-27.
66. Yu C, Chen Y, Cline GW, et al. Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)- associated Phosphatidylinositol 3-Kinase Activity in Muscle. J Biol Chem 2002; 277: 50230-6.
67. Cooper SA, Whaley-Connell A, Habibi J. Renin-angiotensinaldosterone System and Oxidative Stress in Cardiovascular Insulin Resistance. Am J Physiol Heart Circ Physiol 2007; 293: H2009-H23.
68. Mario Pende M, Kozma SC, Jaquet M, et al. Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice. Nature 2000; 408: 994-7.
69. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ. Insulin Receptor Substrate-2 Proteasomal Degradation Mediated by a Mammalian Target of Rapamycin (mTOR)-induced Negative Feedback Downregulates Protein Kinase B-mediated Signaling Pathway in Beta-cells. J Biol Chem 2005; 280: 2282-93.
70. Shah OJ, Wang Z, Hunter T. Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies. Curr Biol 2004; 14: 1650-6.
71. Hamada S, Hara K, Hamada T, et al. Upregulation of the Mammalian Target of Rapamycin Complex 1 Pathway by Ras Homolog Enriched in Brain in Pancreatic β-Cells Leads to Increased β-Cell Mass and Prevention of Hyperglycemia. Diabetes 2009; 58: 1321-32.
72. Donath MY, Ehses JA, Reinecke M, et al. Mechanisms of β cell death in Type 2 Diabetes. Diabetes 2005; 54(Supplement 2).
73. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program. Diabetes Care 1999; 22: 623-34.
74. Ratner RE. An update on the diabetes prevention program. Endocr Pract 2006; 12(Suppl 1): 20-4.
75. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(393-403).
76. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program. Effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-14.
77. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997; 5: 177-285.
78. Bays H, Mandarino L, DeFronzo RA. Role of the adipocytes, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-78.
79. De Fronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes, and atherosclerosis: the missing links. The Claude Bernard Lecture. Diabetologia 2010; 53: 1270-87.
80. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve β-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007; 292: E871-E83.
81. Moriya R, Shirakura T, Ito J, Mashiko S, Seo T. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 2009; 297: E1358-E65.
82. Giannoukakis N, Rudert WA, Trucco M, Robbins PD. Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. The Journal of biological chemistry 2000; 275: 36509-13.
83. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144: 5145-8.
84. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. The Journal of biological chemistry 2003; 278: 471-8.
85. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-43.
86. Salehi M, Aulinger B, D'Alessio DA. Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins. Endocrine Rev 2008; 29(3): 367-79.
87. Efanova IB, Zaitsev SV, Zhivotovsky B, et al. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells: a process dependent on intracellular Ca2+ concentration. J Biol Chem 1998; 273: 33501-7.
88. Iwakura T, Fujimoto S, Kagimoto S, et al. Sustained enhancement of Ca influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun 2000; 271: 422-8.
89. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501-6.
90. Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231-7.
91. U.K. Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.
92. Maedler K, Storling J, Sturis J, et al. Glucose and interleukin- 1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004; 53: 1706-13.
93. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC. Induction of betacell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab 2004; 89: 795-805.
94. Greenwood RH, Mahler RF, Hales CN. Improvement in insulin secretion in diabetes after diazoxide. Lancet 1976; 1: 444-7.